New York, July 01, 2024 (GLOBE NEWSWIRE) -- The global size is expected to reach by 2024 and it is further anticipated to reach a market value of by 2033, according to Dimension Market Research. The market is anticipated to register a CAGR of from 2024 to 2033. The global personalized medicine biomarker market constitutes a comprehensive ecosystem dedicated to identifying and utilizing biomarkers in personalized medicine.
Tailoring treatments to individual patient characteristics optimizes therapeutic outcomes. Biomarkers, such as genetic or molecular signatures, crucially inform diagnosis and guide treatment decisions across diverse applications, shaping a transformative landscape in personalized healthcare. In the context of indication, Oncology is projected to commands a significant market share in this market in 2024.
This dominance is fueled by the global cancer prevalence and the need for targeted treatments. Genomic technology advancements enable personalized approaches, identifying biomarkers for cancer diagnosis and treatment selection. Oncology leads to targeted therapy development, optimizing efficacy, and minimizing interventions.
Cardiology follows, leveraging biomarkers like troponins and BNP for risk prediction and treatment tailoring, reflecting the transformative potential of biomarkers in diverse medical specialties. North America, is anticipate to hold of the global personalized medicine biomarker market in 2024, particularly the United States, plays a pivo.
